Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal regional chemotherapy with mitroxantrone

K H Link1, G Hepp, L Staib

  • 1Department of General Surgery, University Hospital of Ulm, Germany.

Cancer Treatment and Research
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant.

Critical care medicine·2001
Same author

Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications.

Gut·2000
Same author

[The therapy of acute pancreatitis. General guidelines. Working group of the Society for Scientific-Medical Specialties].

Zeitschrift fur Gastroenterologie·2000
Same author

[Reconstruction after gastrectomy. Which patient benefits from a stomach substitute?].

MMW Fortschritte der Medizin·2000
Same author

Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy.

Cancer·2000
Same author

Endotoxin and antiendotoxin antibodies in patients with acute pancreatitis.

The European journal of surgery = Acta chirurgica·2000

Mitoxantrone (NOV) shows promise in intraperitoneal regional chemotherapy (IPRC) for treating malignant ascites and peritoneal carcinomatosis. This study found a 52% overall response rate with manageable regional toxicities.

Area of Science:

  • Oncology
  • Pharmacology
  • Surgical Oncology

Background:

  • Metastatic disease often involves peritoneal spread, leading to malignant ascites or carcinomatosis.
  • Intraperitoneal chemotherapy offers regional drug delivery, potentially improving efficacy and reducing systemic toxicity.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of mitoxantrone (NOV) administered via intraperitoneal regional chemotherapy (IPRC).
  • To assess NOV's effectiveness in patients with malignant ascites and peritoneal carcinomatosis.

Main Methods:

  • Twenty-seven patients with intraperitoneal metastatic solid tumors received cyclic IPRC with mitoxantrone (NOV) at 10 µg/ml.
  • Treatment was administered for malignant ascites (N=16) or peritoneal carcinomatosis (N=11), with 1-5 cycles per patient.

Related Experiment Videos

  • Response and toxicity were assessed using World Health Organization (WHO) criteria.

    • Main Results:

    • An overall response rate (CR+PR) of 52% was observed (56% for malignant ascites, 45% for peritoneal carcinomatosis).
    • No systemic toxicities were reported.
    • Regional toxicities included bacteremia (3.2%), pain (1.6%), a small bowel stricture (1 patient), and a small bowel perforation (1 patient).

    Conclusions:

    • Mitoxantrone (NOV) demonstrates significant efficacy in IPRC for managing malignant ascites and peritoneal carcinomatosis.
    • IPRC with NOV is associated with tolerable regional toxicities, suggesting its potential as a treatment option.